T2 Biosystems - TTOO Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $3.00
  • Forecasted Upside: -51.22%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$6.15
▲ +0.22 (3.71%)

This chart shows the closing price for TTOO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New T2 Biosystems Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TTOO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TTOO

Analyst Price Target is $3.00
▼ -51.22% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for T2 Biosystems in the last 3 months. The average price target is $3.00, with a high forecast of $3.00 and a low forecast of $3.00. The average price target represents a -51.22% upside from the last price of $6.15.

This chart shows the closing price for TTOO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 1 investment analysts is to hold stock in T2 Biosystems. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/29/2024Canaccord Genuity GroupLower TargetHold ➝ Hold$12.00 ➝ $3.00Low
10/14/2022Canaccord Genuity GroupReiterated RatingBuy ➝ HoldLow
10/14/2022Canaccord Genuity GroupDowngradeBuy ➝ Hold$1,250.00 ➝ $250.00Low
7/7/2022Alliance Global PartnersDowngradeBuy ➝ NeutralN/A
7/7/2022BTIG ResearchDowngradeBuy ➝ NeutralN/A
2/18/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$15,000.00 ➝ $7,500.00High
2/18/2022Alliance Global PartnersUpgradeNeutral ➝ Buy$3,500.00Low
5/14/2021SVB LeerinkReiterated RatingBuy$15,000.00Medium
3/5/2021Alliance Global PartnersLower TargetNeutral$12,000.00 ➝ $8,250.00High
1/27/2021JonestradingReiterated RatingBuy$17,500.00High
1/27/2021Alliance Global PartnersDowngradeBuy ➝ Neutral$13,000.00 ➝ $12,000.00High
1/27/2021SVB LeerinkLower TargetOutperform$20,000.00 ➝ $15,000.00High
11/5/2020Alliance Global PartnersBoost TargetBuy$8,250.00 ➝ $13,000.00Medium
11/5/2020SVB LeerinkBoost TargetOutperform$15,000.00 ➝ $20,000.00High
10/7/2020BTIG ResearchInitiated CoverageBuy$12,500.00Low
8/12/2020SVB LeerinkBoost TargetOutperform$10,000.00 ➝ $15,000.00High
5/6/2020SVB LeerinkReiterated RatingOutperform$25,000.00 ➝ $10,000.00High
1/23/2020Alliance Global PartnersUpgradeNeutral ➝ BuyHigh
11/26/2019Janney Montgomery ScottDowngradeBuy ➝ NeutralHigh
11/21/2019HC WainwrightReiterated RatingHoldMedium
9/12/2019SVB LeerinkSet TargetBuy$25,000.00Low
9/12/2019Janney Montgomery ScottUpgradeNeutral ➝ Buy$30,000.00High
9/11/2019Janney Montgomery ScottReiterated RatingFair Value ➝ Neutral$10,000.00High
8/7/2019HC WainwrightReiterated RatingHoldMedium
8/1/2019Alliance Global PartnersDowngradeBuy ➝ Neutral$25,000.00 ➝ $2,000.00High
7/31/2019HC WainwrightDowngradeBuy ➝ NeutralHigh
7/31/2019Cantor FitzgeraldDowngradeOverweight ➝ NeutralHigh
7/31/2019Janney Montgomery ScottDowngradeBuy ➝ NeutralHigh
(Data available from 6/24/2019 forward)

News Sentiment Rating

0.30 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/27/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/26/2024
  • 4 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/26/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/25/2024
  • 3 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
5/25/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/24/2024

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
T2 Biosystems logo
T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens. In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Read More

Today's Range

Now: $6.15
Low: $5.94
High: $6.40

50 Day Range

MA: $4.30
Low: $2.72
High: $6.06

52 Week Range

Now: $6.15
Low: $2.60
High: $70.00

Volume

92,428 shs

Average Volume

307,147 shs

Market Capitalization

$54.06 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.09

Frequently Asked Questions

What sell-side analysts currently cover shares of T2 Biosystems?

The following sell-side analysts have issued reports on T2 Biosystems in the last twelve months: Canaccord Genuity Group Inc., and StockNews.com.
View the latest analyst ratings for TTOO.

What is the current price target for T2 Biosystems?

1 Wall Street analysts have set twelve-month price targets for T2 Biosystems in the last year. Their average twelve-month price target is $3.00, suggesting a possible downside of 51.2%. Canaccord Genuity Group Inc. has the highest price target set, predicting TTOO will reach $3.00 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of $3.00 for T2 Biosystems in the next year.
View the latest price targets for TTOO.

What is the current consensus analyst rating for T2 Biosystems?

T2 Biosystems currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in TTOO, but not buy more shares or sell existing shares.
View the latest ratings for TTOO.

What other companies compete with T2 Biosystems?

How do I contact T2 Biosystems' investor relations team?

T2 Biosystems' physical mailing address is 101 HARTWELL AVENUE, LEXINGTON MA, 02421. The medical equipment provider's listed phone number is (781) 761-4646 and its investor relations email address is [email protected]. The official website for T2 Biosystems is www.t2biosystems.com. Learn More about contacing T2 Biosystems investor relations.